Concepedia

David Köhler

DK

36

Publications

2.8K

Citations

26

H-Index

1986

Active since

Affiliations

National Cancer Institute(Current)

National Institutes of Health

National Cancer Institute

Novartis (Switzerland)

National Institutes of Health Clinical Center

David Köhler is an author at National Cancer Institute specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Top concepts

Publications per year

1986–2022

36

Publications

36

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

W D Figg, William Dahut, Paul H. Duray et al. · PubMed · 2001 · 304 citations

Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer

J. Zujewski, Ivan D. Horak, C.J. Bol et al. · Journal of Clinical Oncology · 2000 · 265 citations

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

Wyndham H. Wilson, G Bryant, Susan E. Bates et al. · Journal of Clinical Oncology · 1993 · 244 citations

Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.

V. Sandor, Virginia Stark-Vancs, Deborah A. Pearson et al. · Journal of Clinical Oncology · 1998 · 237 citations

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Michelle A. Rudek, William D. Figg, Valerie Dyer et al. · Journal of Clinical Oncology · 2001 · 157 citations

Rows per page

1–5 of 36